This article mentions Brilacidin as a promising drug in late-stage clinical development for the treatment of MRSA infections. The author isn't very familiar with B because he describes the treament as a 7-day regimen. Also I think the expected US launch date should be 2018, not 2019. Nevertheless, it's good to see B getting more attentions.

http://www.ptcommunity.com/journal/article/fu...infections